Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-10
2011-05-10
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S260000
Reexamination Certificate
active
07939530
ABSTRACT:
Lymphoma is treated using therapeutic combinations of PDX and gemcitabine by administering to a patient suffering from lymphoma a therapeutically effective amount of PDX in combination with a therapeutically effective amount of gemcitabine. The two agents can be administered together or in either order, although administration of PDX followed by gemcitabine is preferred. As in the case of MTX and Ara-C, synergism is observed, but the extent of the synergism is greater. Further, test results indicate that mechanism of action for combinations of PDX and Gem is different than for MTX and Ara-C, with more emphasis on induction of apoptosis.
REFERENCES:
patent: 5354751 (1994-10-01), DeGraw et al.
patent: 6323205 (2001-11-01), Sirotnak et al.
patent: 7622470 (2009-11-01), O'Connor et al.
patent: 2005/0267117 (2005-12-01), O'Connor et al.
patent: 98/02163 (1998-01-01), None
Tonkinson et al., “Cell Cycle Modulation by a Multitargeted Antifolate, LY231514, Increases the Cytotoxicity and Antitumor Activity of Gemcitabine in HT29 Colon Carcinoma” Cancer Research (1999) vol. 59 pp. 3671-3676.
Giovanetti et al., “Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines” Clinical Cancer Research (2004) vol. 10 pp. 2936-2943.
Teicher et al., “Treatment Regimens Including the Multitargeted Antifolate LY231514 in Human Tumor Xenografts”Clinical Cancer Research (2000) vol. 6 pp. 1016-1023.
Akutsu M et al. “Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro.” Leukemia. Mar. 12, 2002, pp. 1808-1817. vol. 16.
Cadman Ed et al. “Mechanism of Synergistic Cell Killing when Methotrexate Precedes Cytosine Arabinoside.” J. Clin Invest. 1979. pp. 788-797. vol. 64.
Chau I et al. “Gemcitibine and its combinations in the treatment of malignant lymphoma.” Clincal Lymphoma. 2002. pp. 97-104. vol. 3, No. 11.
DeGraw et al. “Synthesis and Antitumor Activity of 10-Propargy1-10-deazaanninopterin.” Journal of Medical Chemistry. 1993. pp. 2228-2231. vol. 36.
Hoovis ML et al. “Enhancement of the Antiproliferative Action of 1-β-D-Arabinofuranosylcytosine by Methotrexate in Murine Leukemic Cells (L5178Y).” Cancer Research. 1973. pp. 521-525. vol. 33.
Khokhar Nushima et al. “Experimental Therapeutices with a New 10-Deazaaminopterin in Human Mesothelioma: Further Improving Efficacy through Structural Design, Pharmacologic Modulation at the Level of MRP ATPases, and Combines Therpay with Platinums.” Clinical Cancer Research. 2001. pp. 3199-3205. vol. 7.
Krug Lee et al. “10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.” Clinical Cancer Research: An official journal of the American Association for Cancer Research 2003. pp. 2072-2078. vol. 9, No. 6.
Sirotnak F.M. et al. “Co-administration of Probenecid, an Inhibitor of a cMOAT/MRP-like Plasma Membrane ATPase, Greatly Enhanced the Efficacy of a New 10-Deazaaminopterin against Human Solid Tumors in Vivo.” Clinical Cancer Research. 2000. pp. 3705-3712. vol. 6.
Vrhovac Radovan et al. “A novel antifolate 10-propargyl-10-deazaaminopterin (PDX) displays synergistic effects with gemcitabine in non-Hodgkin's lymphoma models in vitro and in vivo.” 45th Annual Meeting of the American Society of Hematology. Nov. 16, 2003. pp. 288b. vol. 102, No. 11.
Wang E S et al. “Activity of a novel anti-folate (PDX, 10 propargy1-10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.” Leukemia and Lymphoma. Jun. 1, 2003. pp. 1027-1035. vol. 44, No. 6.
Wang et al.“PDX, a Novel Antifolate with Potent in Vitro and in Vivo Activity in Non-Hodgkin's Lymphoma.” Developmental Hematology and the program for Molecular Pharmacology and Experimental Therapeutics. Abstract 2565.
O'Connor Owen A
Sirotnak Francis
Larson & Anderson LLC
Olson Eric S
Sloan-Kettering Institute for Cancer Research
LandOfFree
Treatment of lymphoma using 10-propargyl-10-deazaaminopterin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of lymphoma using 10-propargyl-10-deazaaminopterin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of lymphoma using 10-propargyl-10-deazaaminopterin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641289